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doi:10.1016/j.kjms.2011.06.001Abstract This prospective study was to investigate the possible risk factors for the leakage of
chemotherapeutic agent into the systemic circulation after transcatheter arterial chemoem-
bolization (TACE) of hepatocellular carcinoma (HCC). Peripheral plasma concentrations of
chemotherapeutic agents were determined at 1 hour and 72 hours after TACE by high-
performance liquid chromatography in 53 patients. HCC were divided into three types namely
single nodule (<5 cm), multiple nodules (all <5 cm), and main nodule measuring 5 cm or more.
Forty-four patients (83%) showed detectable chemotherapeutic concentrations within 72 hours
after TACE. Patients with single nodular-type HCC had lower incidence of detectable plasma
chemotherapeutic agents after TACE than the other two groups (all p< 0.05). The injected
doses of lipiodol, epirubicin, and mitomycin C were lower in patients without detection than
in patients with detectable chemotherapeutic agents (all p< 0.05). Multivariate logistic
regression showed that tumor type and injected dose of lipiodol were two independent risk
factors for the leakage of mitomycin C at 1 hour after TACE (all p< 0.05), and the injected
dose of mitomycin C was the risk factor for the leakage of epirubicin at 1 hour after TACE
(p< 0.05). In conclusion, multiple nodular type and large nodule measuring 5 cm or more have
a risk of leakage of mitomycin C after TACE. Injected dose of lipiodol and mitomycin C as riskter and Division of Hepatobiliary Medicine, Department of Internal Medicine, Kaohsiung Medical
Road, Kaohsiung 807, Taiwan.
m.tw (Z.-Y. Lin).
vier Taiwan LLC. All rights reserved.
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Characteristics S
Patients, n
Sex (M/F)*
Age (y)*
Etiology*
Chronic hepatitis B
Chronic hepatitis C
Unknown
Cirrhosis ()**
Child-Pugh class (A/B)*
Arterioportal shunt ()*
Data are given as the median and ra
The Kruskal-Wallis test or Chi-squar
*p> 0.05; **p< 0.05.factor for the leakage of mitomycin C and epirubicin respectively may be because of compe-
tition of their injected volume within the limited space of target.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Introduction
Transcatheter arterial chemoembolization (TACE) is a palli-
ative method for the management of hepatocellular carci-
noma (HCC) [1e3]. However, the optimal schedule, best
anticancer agent, and best technique for TACE are still
unclear [3e5]. Several embolic agents have been used in
TACE. Although lipiodol [5e7] and absorbable gelatin
sponge or starch microspheres [8,9] have been applied in
TACE, there is no strong evidence to show the advantage of
these agents to delay the clearance of chemotherapeutic
agent from the liver after TACE. Application of nonabsorb-
able polyvinyl alcohol microspheres as the embolic agent in
TACE was also reported of no influence on the reduction in
the systemic toxicity of chemotherapeutic agent in liver
metastases [9,10]. On the other hand, chronic hepatitis B
and C viral infections are two major etiologies in developing
HCC [11,12]. Flare-up of hepatitis because of reactivation of
hepatitis B or hepatitis C virus is a well-known complication
in patients with malignant disease who receive chemo-
therapy [13,14]. Although TACE is not a systemic chemo-
therapy, there are evidences showing the influence of TACE
on replication of hepatitis B or hepatitis C virus [15e18].
Moreover, the plasma concentrations of the leaked chemo-
therapeutic agents after TACE may not be enough to exert
their chemotherapeutic effects on the residual cancer cells.
This may increase the risk of chemotherapeutic resistance
of the residual cancer cells. Therefore, understanding the
risk factors for the leakage of chemotherapeutic agent after
TACE is very important in long-term management of these
patients. The purpose of this prospective study was to
investigate these risk factors, which had not been clarified
in the previous studies.groups of patients with hepat
ingle nodule
(<5 cm)
Multiple no
(all <5 c
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56 (37e76) 70 (50e
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2/15 4/20
nge.
e test was applied for statisticalPatients and methodsPatients
From February 2008 to February 2009, a total of 53 patients
with HCC who planned to receive TACE were included
(Table 1). The diagnosis of HCC was based on fine-needle
aspiration cytology and/or biopsy. HCC were divided into
three types namelysingle nodule (<5 cm), multiple nodules
(all <5 cm), and main nodule measuring 5 cm or more with
or without daughter nodules. For 17 patients with single
nodule of HCC, 10 patients received further local ablation
therapy and 1 patient received operative resection at least
1 week after TACE. The remaining six patients refused
operative resection or local ablation therapy because of
their personal reasons. The diagnosis of arterioportal shunt
was based on the pre-TACE angiography and was made by
a radiologist. The patients with large arterioportal shunts,
which needed to be particularly treated by implantation of
various sizes of Nester embolization coils (Cook, Inc.,
Bloomington, IN, USA), were excluded. None of the patients
had shunts communicating with the hepatic arterial system
and the hepatic venous system. The diagnosis of liver
cirrhosis was based on a coarse and contracted liver on
abdominal sonography with at least one of the following
two positive findings, including (1) esophageal or cardiac
varices found by endoscopic examination and (2) presence
of portal collateral circulation with or without spleno-
megaly on computed tomography. Chronic hepatitis B or
hepatitis C was diagnosed by positive serum hepatitis B
surface antigen or antihepatitis C antibody for more than 6
months. This study was approved by the Institutionalocellular carcinoma
dules
m)
Main nodule 5 cm with or
without daughter nodules
Total
12 53
9/3 39/14
85) 62.5 (44e78) 63 (37e85)
6 22
5 29
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11/1 40/13
9/2 34/6
4/8 10/43
analysis.
Leakage of chemotherapeutic agents after TACE 433Review Board of our hospital. Each patient gave informed
consent to participate in this study.
Methods
Procedure of TACE
TACE was carried out by infusion of the mixture of chemo-
therapeutic agents and lipiodol (Lipiodol Ultra-Fluid; Guer-
bet, Aulnay-sous-Bois, France) into the lesion followed
by embolization of the supplying arteries using various sizes
of nonabsorbable Embosphere microspheres (BioSphere
Medical, Inc., Rockland, MA, USA), or absorbable agents
(Avitene Microfibrillar Collagen Hemostat; MedChem Prod-
ucts, Inc., Woburn, MA, USA), or gelfoam particles of
1e2 mm in size (Pharmacia & Upjohn Company, Kalamazoo,
MI, USA). Selection of nonabsorbable or absorbable embolic
agent was based on the size of the tumor and the patterns of
the supplying arteries and was decided by both the radiolo-
gist and patient because only gelfoam could be paid by the
national health insurance. Fifty-one patients received both
epirubicin (Pharmacia & Upjohn S.p.A, Milan, Italy) and
mitomycin C (Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan) as
chemotherapeutic agents and 2 patients received epirubicin
alone. Each vial of chemotherapeutic agent (epirubicin
10 mg/vial, mitomycin C 2 mg/vial) was dissolved by 2 mL
contrast medium (Ultravist; Bayer Schering Pharma AG,
Berlin, Germany). The desired doses of chemotherapeutic
agents and lipiodol in separate syringes were well mixed by
a connector before injecting into the lesion. The doses of
chemotherapeutic agents and lipiodol were decided by the
radiologist based on the following criteria. The dose of total
injected lipiodol depended on the sum of the diameters of
target nodules (1 mL lipiodol for 1 cm diameter). The
maximum dose of lipiodol was 10 mL in each session of TACE.
The estimated volume of total injected chemotherapeutic
agents was twice of lipiodol volume. However, the actual
injected volume of chemotherapeutic agents could be
reduced because of the condition of the patient, such as
presence of leucopenia. To minimize the possible damage of
hepatic parenchyma caused by TACE, all patients received
superselective procedure for embolization of the tumor. The
procedure of TACE was complete when all detectable
supplying arteries of the tumor and arterioportal shunt were
embolized evidenced by immediate post-TACE angiography.
The whole procedure of TACE was carried out by an inde-
pendent radiologist who did not know the contents of the
study. Totally, three radiologists with different experience in
TACE procedure (DKW, 19 years; PMCS, 10 years; MLC,
2 years) were involved.
Determination of epirubicin and mitomycin C
concentrations in plasma
Plasma concentrations of chemotherapeutic agents (epi-
rubicin and mitomycin-C) were measured at 1 hour and 72
hours after TACE. The plasma used for the study were
collected immediately drawn from the peripheral veins of
the patients and were stored at 20C for further investi-
gation. Plasma concentrations of epirubicin and mitomycin C
were detected by high-performance liquid chromatography(HPLC) system using Hitachi pump L-2130 and Hitachi UV-Vis
detector L-2420 (Hitachi High-Technologies Corp., Tokyo,
Japan) with Waters Model 717 Plus HPLC autoinjector
(American Instrument Exchange, Inc., Haverhill, MA, USA).
Epirubicin was detected at 480 nm wavelength and mito-
mycin C was detected at 368 nm. The results were analyzed
by Hitachi Model D-2000 chromatography Data Station soft-
ware (Hitachi High-Technologies Corporation, Tokyo, Japan).
The detection limits for epirubicin and mitomycin C were all
2 ng/mL. The whole procedure was performed by the same
person. The coefficient of variation values for intra-assay
(calculation from five measurements) were 3.5% and 7.6%
for epirubicin and mitomycin C, respectively.
Statistical analysis
All data for continuous variables were expressed as median
and range. Difference of medians was analyzed by the
Mann-Whitney U test or Kruskal-Wallis test. Fisher’s exact
test or Chi-square test was used to compare proportions
between groups. Correlation analysis was investigated by
the calculation of a correlation coefficient (r). Multivariate
logistic regression was applied to investigate the risk
factors for leakage of chemotherapeutic agents after TACE.
The statistical significance was defined as p value less than
0.05.
Results
Patients with main HCC nodule measuring 5 cm or more
received higher injected doses of chemotherapeutic agents
and lipiodol than the other two groups of patients (Table 2).
The injected doses of lipiodol were lower in patients with
single nodule of HCC than in patients with multiple nodules
of HCC. Plasma epirubicin and mitomycin C were detected
at 62.3% (nZ 33, 7.2 ng/mL and 2.2e65.8 ng/mL) and
64.7% (nZ 33, 4.8 ng/mL and 2.6e19 ng/mL), respectively
at 1 hour after TACE, and 15.1% (nZ 8, 16.7 ng/mL and
6.1e32.2 ng/mL) and 2% (nZ 1, 4.8 ng/mL), respectively
at 72 hours after TACE (Fig. 1A and B). Overall, 44 patients
(83%) showed detectable plasma epirubicin and/or mito-
mycin C concentrations within 72 hours after TACE (Table
3). Patients with single nodular-type HCC had significant
lower incidence of detectable plasma chemotherapeutic
agents than the other two groups of patients. The injected
doses of lipiodol, epirubicin, and mitomycin C were signif-
icantly lower in patients without detection than in patients
with detectable plasma chemotherapeutic agents. Plasma
epirubicin and mitomycin C concentrations at 1 hour after
TACE showed positive correlation with their corresponding
injected doses (rZ 0.44, p< 0.01 for epirubicin; rZ 0.47,
p< 0.001 for mitomycin C). Plasma epirubicin concentra-
tions at 72 hours after TACE also showed positive correla-
tion with their corresponding injected doses (rZ 0.4,
p< 0.01) and their corresponding plasma concentrations at
1 hour after TACE (rZ 0.31, p< 0.05). Tumor type, injec-
ted doses of chemotherapeutic agents and lipiodol, lip-
iodol/contrast medium ratio, presence of arterioportal
shunt, using absorbable or nonabsorbable embolic agent
and doctors with different experience were used as items in
multivariate logistic regression. Tumor type (p< 0.05) and
Table 2 The injected doses of chemotherapeutic agents and lipiodol in three groups of patients with hepatocellular
carcinoma
Chemotherapeutic agents Single nodule (<5 cm) Multiple nodules
(all <5 cm)
Main nodule 5 cm with or
without daughter nodules
Total
Injected epirubicin (mg) 10*** (2e20) 10*** (2.5e20) 20*** (10e30) 10 (2e30)
Injected mitomycin C (mg) 2** (0.4e4) 2* (0.5e4) 4* (1e6) 2 (0.4e6)
Lipiodol (mL) 2.5**** (1.5e4) 5**** (2e10) 7.5**** (3e10) 4 (1.5e10)
Lipiodol/contrast medium ratio 0.75 (0.5e2.5) 0.85 (0.5e2.67) 0.83 (0.5e2.5) 0.83 (0.5e2.67)
Data are given as the median and range.
The Kruskal-Wallis test, Mann-Whitney test, or Chi-square test was applied for statistical analysis.
*p< 0.05; **p< 0.01; ***p< 0.001; ****p< 0.0001.
434 M.-Y. Hsieh et al.injected dose of lipiodol (p< 0.05) were two independent
risk factors for the leakage of mitomycin C at 1 hour after
TACE, and the injected dose of mitomycin C (p< 0.05) was
the risk factor for the leakage of epirubicin at 1 hour after
TACE investigated by multivariate logistic regression.
Five patients (9.4%) showed increasing plasma epirubicin
(four patients) or mitomycin C (one patient) concentrations
at 72 hours after TACE (Fig. 1A and B) (Table 4). Patients
with main HCC nodule measuring 5 cm or more had signifi-
cantly higher incidence of increasing plasma epirubicin or
mitomycin C concentrations at 72 hours after TACE than
patients with other types of HCC (4/12 vs. 1/41, p< 0.01).
Patients with arterioportal shunt also had significantlyFigure 1. Plasma concentrations of (A) epirubicin and (B)
mitomycin-C at 1 hour and 72 hours after TACE of hepatocellular
carcinoma. TACEZ transcatheter arterial chemoembolization.higher incidence of increasing plasma epirubicin or mito-
mycin C concentrations at 72 hours after TACE than
patients without arterioportal shunt (3/10 vs. 2/43,
p< 0.05). Multivariate logistic regression using tumor type
and presence of arterioportal shunt as items showed that
presence of arterioportal shunt might be the risk factor for
increasing plasma chemotherapeutic agents at 72 hours
after TACE (pZ 0.0718).Discussion
The present results showed high incidence of leakage of
injected chemotherapeutic agents within 72 hours after
TACE. Leakage mainly occurred soon after TACE. After-
ward, the plasma concentrations of leaked chemothera-
peutic agents decreased gradually. Because the systemic
circulated mitomycin C has very short half-life, most
patients showed undetectable peripheral plasma concen-
trations of mitomycin C at 72 hours after TACE. Therefore,
we applied data obtained 1 hour after TACE to investigate
the risk factors for the leakage of chemotherapeutic agents
after TACE. The present results showed that the tumor type
and the injected doses of lipiodol were two independent
risk factors for the leakage of mitomycin C at 1 hour after
TACE. The vascularity of HCC usually will increase with
increasing tumor size [19]. This indicates that the tumor-
related draining venous system is more prominent in larger
HCC than in smaller HCC. The injected chemotherapeutic
agents thus had higher probability to leak out in larger HCC
measuring more than 5 cm than in single nodular-type HCC.
On the other hand, embolization of multiple nodules of
HCC usually needed to inject chemotherapeutic agents
to different parts of the liver. This also will increase the
probability to leak out the injected chemotherapeutic agents
to systemic circulation. Therefore, patients with multiple
nodular-typeHCChad higher incidence of leakage of injected
chemotherapeutic agents than patients with single nodular-
type HCC. Because lipiodol cannot absorb chemotherapeutic
agents, injection of lipiodol may compete with the injected
volume of chemotherapeutic agents within the limited space
of target and thus become a risk factor for the leakage of
mitomycin C. The injected dose of mitomycin C becoming
a risk factor for the leakage of epirubicin at 1 hour after TACE
may also be because of competition of their injected volume
within the limited space of target. The new drug-eluting
microspheres, which can absorb chemotherapeutic agents,
Table 3 Comparison between patients with or without detectable plasma epirubicin and/or mitomycin C concentrations
within 72 hours after TACE for hepatocellular carcinoma
Characteristics Detectable (nZ 44) Undetectable (nZ 9)
Sex (M/F) 32/12 7/2
Age (y) 67.5 (44e85) 59 (37e80)
Cirrhosis () 33/11 7/2
Arterioportal shunt () 10/34 0/9
Tumor type
Single nodule (<5 cm)* 10 7
Multiple nodules (all <5 cm)* 22 2
Main nodule 5 cm daughter nodules* 12 0
TACE operator (Doctor DKW/PMCS/MLC) 14/21/9 1/7/1
Injected lipiodol (mL)* 4.5 (1.5e10) 2.5 (2e5)
Lipiodol/contrast medium ratio 0.83 (0.5e2.5) 0.93 (0.5e2.67)
Embolic agent
Nonabsorbable 31 5
Absorbable 13 4
Injected epirubicin (mg)** 17 (2e30) 10 (2.5e10)
Injected mitomycin C (mg)* 2 (0.4e6) 1 (0.5e2)
Data are given as the median and range.
The Mann-Whitney U test, Fisher’s exact test, or Chi-square test was applied for statistical analysis.
*p< 0.05; **p< 0.01.
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effects within the tumor [20]. The reasonwhy the risk factors
for the leakage of mitomycin C do not become risk factors for
the leakage of epirubicin needs further investigation.
Few patients in the present study had increasing plasma
epirubicin or mitomycin C concentrations at 72 hours after
TACE. This indicates that the injected chemotherapeutic
agents were initially plugged within the lesion and were
released subsequently. The present study did not include
patients with large arterioportal shunts because theseTable 4 Characteristics of five patients with increasing plasma
TACE as compared with those at 1 hour after TACE
Patient 1 2
Sex Male Mal
Age (y) 84 62
Plasma concentration after TACE (ng/mL)
1 h 2.9 (M) 0 (E)
72 h 4.8 (M) 32.2 (E
Cirrhosis Yes Yes
Arterioportal shunt Yes No
Tumor type Multiple nodules M N
TACE operator (Doctor) PMCS PMCS
Lipiodol/contrast medium ratio 1 1.25
Embolic agents Nonabsorbable Absorb
EZ epirubicin; MZmitomycin C; M NZmain nodule 5 cm with o
moembolization.shunts are very difficult to be completely obliterated and
leakage of injected chemotherapeutic agents can be
expected. However, our result still showed that the pres-
ence of small arterioportal shunts, which did not needed to
be treated by coil, might be a risk factor for the delay in
releasing chemotherapeutic agents into systemic circula-
tion after TACE. This implies that even small arterioportal
shunt might have the tendency to rapid recanalization soon
after TACE by our method. The new drug-eluting micro-
spheres not only can absorb chemotherapeutic agents butepirubicin or mitomycin C concentrations at 72 hours after
3 4 5
e Female Male Male
51 67 63
0 (E) 9.4 (E) 0 (E)
) 28.6 (E) 21 (E) 12.3 (E)
Yes Yes Yes
Yes Yes No
M N M N M N
MLC DKW MLC
1 0.5 0.83
able Nonabsorbable Absorbable Nonabsorbable
r without daughter nodules; TACEZ transcatheter arterial che-
436 M.-Y. Hsieh et al.also can prevent recanalization of the embolized vessel
[21]. This may be a good modality to prevent delay in
releasing injected chemotherapeutic agent after TACE.
Further study using large number of patients may be
necessary to clarify this issue.
In the present study, HCC was classified into three types
based on the intrahepatic tumor burden rather than
American Joint Committee on Cancer TNM system or other
staging systems. This is because that the intrahepatic tumor
burden was the main determinant for the injected doses of
chemotherapeutic agents, lipiodol, and embolic agent. On
the other hand, 24.5% (13/53) patients did not have
concomitant liver cirrhosis based on our criteria. Because
we did not perform liver biopsy in each patient, the ratio of
noncirrhotic patients in the present study might be over-
estimated. However, this will not influence our results
because the factor of arterioportal shunt, which may exist
in patients with cirrhosis, is considered in the analysis of
data.
The present study indicates that the transient leakage of
the injected chemotherapeutic agent into systemic circu-
lation after TACE is very common. Tumor type and injected
dose of lipiodol may be risk factors for the leakage of
mitomycin C after TACE. High-injected dose of mitomycin C
may interfere with the stasis of epirubicin within the tumor
and become a risk factor for the leakage of epirubicin after
TACE.
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